Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 43 | 2023 | 1371 | 6.850 |
Why?
|
| Cancer Pain | 23 | 2023 | 312 | 4.770 |
Why?
|
| Palliative Care | 31 | 2023 | 2037 | 2.720 |
Why?
|
| Neoplasms | 55 | 2024 | 15193 | 2.660 |
Why?
|
| Pain Management | 12 | 2019 | 668 | 2.290 |
Why?
|
| Methadone | 6 | 2023 | 195 | 2.030 |
Why?
|
| Opioid-Related Disorders | 9 | 2023 | 394 | 1.880 |
Why?
|
| Fentanyl | 7 | 2023 | 148 | 1.620 |
Why?
|
| Levorphanol | 3 | 2023 | 14 | 1.600 |
Why?
|
| Hydromorphone | 6 | 2022 | 58 | 1.560 |
Why?
|
| Pain | 12 | 2023 | 1658 | 1.550 |
Why?
|
| Chronic Pain | 3 | 2023 | 238 | 1.140 |
Why?
|
| Morphine | 10 | 2023 | 308 | 1.130 |
Why?
|
| Outpatients | 10 | 2023 | 462 | 1.110 |
Why?
|
| Pain, Intractable | 3 | 2018 | 171 | 1.040 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2020 | 1303 | 1.000 |
Why?
|
| Delirium | 7 | 2020 | 207 | 0.840 |
Why?
|
| Oxymorphone | 1 | 2021 | 9 | 0.790 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 30 | 0.730 |
Why?
|
| Drug Storage | 2 | 2016 | 29 | 0.630 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 50 | 0.600 |
Why?
|
| Oncologists | 1 | 2019 | 134 | 0.580 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 289 | 0.570 |
Why?
|
| Hydrocodone | 2 | 2014 | 55 | 0.520 |
Why?
|
| Refuse Disposal | 1 | 2014 | 10 | 0.500 |
Why?
|
| Humans | 81 | 2024 | 261506 | 0.490 |
Why?
|
| Neuralgia | 1 | 2018 | 251 | 0.490 |
Why?
|
| Hospital Units | 1 | 2013 | 38 | 0.470 |
Why?
|
| Oncology Service, Hospital | 1 | 2013 | 48 | 0.470 |
Why?
|
| Proxy | 1 | 2012 | 23 | 0.440 |
Why?
|
| Ambulatory Care | 3 | 2023 | 554 | 0.420 |
Why?
|
| Clinical Competence | 2 | 2019 | 1270 | 0.410 |
Why?
|
| Treatment Refusal | 1 | 2012 | 128 | 0.400 |
Why?
|
| Middle Aged | 43 | 2024 | 86204 | 0.400 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 5687 | 0.390 |
Why?
|
| Survivors | 1 | 2016 | 1031 | 0.390 |
Why?
|
| Patient Care Team | 2 | 2014 | 795 | 0.370 |
Why?
|
| Male | 46 | 2024 | 123000 | 0.360 |
Why?
|
| Haloperidol | 3 | 2020 | 64 | 0.350 |
Why?
|
| Female | 46 | 2024 | 141928 | 0.340 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 610 | 0.340 |
Why?
|
| Linear Models | 3 | 2017 | 1085 | 0.330 |
Why?
|
| Antipsychotic Agents | 3 | 2020 | 414 | 0.320 |
Why?
|
| Cancer Care Facilities | 5 | 2021 | 884 | 0.320 |
Why?
|
| Physicians | 3 | 2023 | 882 | 0.310 |
Why?
|
| Retrospective Studies | 16 | 2023 | 37905 | 0.300 |
Why?
|
| Administration, Cutaneous | 3 | 2016 | 141 | 0.300 |
Why?
|
| Substance-Related Disorders | 3 | 2024 | 524 | 0.290 |
Why?
|
| Algorithms | 1 | 2018 | 3890 | 0.290 |
Why?
|
| Attitude of Health Personnel | 4 | 2022 | 918 | 0.280 |
Why?
|
| Cordotomy | 2 | 2019 | 46 | 0.280 |
Why?
|
| Hospice Care | 3 | 2018 | 156 | 0.270 |
Why?
|
| Pandemics | 4 | 2023 | 1559 | 0.270 |
Why?
|
| Adaptation, Psychological | 4 | 2024 | 764 | 0.270 |
Why?
|
| Telemedicine | 2 | 2022 | 471 | 0.260 |
Why?
|
| Drug Overdose | 2 | 2023 | 81 | 0.260 |
Why?
|
| Fatigue | 3 | 2017 | 1239 | 0.250 |
Why?
|
| Terminal Care | 3 | 2020 | 447 | 0.250 |
Why?
|
| Aged | 23 | 2021 | 70117 | 0.230 |
Why?
|
| Lactams | 1 | 2023 | 24 | 0.230 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2023 | 29 | 0.230 |
Why?
|
| Medical Oncology | 6 | 2023 | 1423 | 0.230 |
Why?
|
| Psychological Tests | 1 | 2024 | 131 | 0.230 |
Why?
|
| Acupuncture | 2 | 2020 | 22 | 0.230 |
Why?
|
| Ritonavir | 1 | 2023 | 67 | 0.220 |
Why?
|
| Adult | 23 | 2023 | 77950 | 0.220 |
Why?
|
| Proline | 1 | 2023 | 130 | 0.220 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 92 | 0.220 |
Why?
|
| Hot Flashes | 2 | 2020 | 37 | 0.210 |
Why?
|
| Integrative Medicine | 1 | 2023 | 39 | 0.210 |
Why?
|
| Referral and Consultation | 3 | 2023 | 899 | 0.210 |
Why?
|
| Acupuncture Therapy | 2 | 2020 | 89 | 0.210 |
Why?
|
| Leucine | 1 | 2023 | 352 | 0.210 |
Why?
|
| Benzodiazepines | 2 | 2020 | 170 | 0.200 |
Why?
|
| Integrative Oncology | 1 | 2021 | 30 | 0.200 |
Why?
|
| Patient Care Planning | 1 | 2023 | 297 | 0.200 |
Why?
|
| Tobacco Use | 2 | 2018 | 54 | 0.200 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 44 | 0.190 |
Why?
|
| Prescription Drug Monitoring Programs | 1 | 2020 | 11 | 0.190 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2022 | 56 | 0.190 |
Why?
|
| Substance Abuse Detection | 1 | 2020 | 64 | 0.190 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 49 | 0.180 |
Why?
|
| Receptors, Opioid | 1 | 2020 | 35 | 0.180 |
Why?
|
| Self Report | 1 | 2024 | 756 | 0.180 |
Why?
|
| Psychomotor Agitation | 1 | 2020 | 78 | 0.180 |
Why?
|
| Mind-Body Therapies | 1 | 2020 | 29 | 0.180 |
Why?
|
| Esophagitis | 1 | 2021 | 202 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2023 | 4938 | 0.180 |
Why?
|
| Opium Dependence | 1 | 2019 | 1 | 0.180 |
Why?
|
| Gastrostomy | 1 | 2021 | 180 | 0.170 |
Why?
|
| Symptom Assessment | 2 | 2023 | 267 | 0.170 |
Why?
|
| Prospective Studies | 8 | 2024 | 12873 | 0.170 |
Why?
|
| Glutamine | 1 | 2021 | 299 | 0.170 |
Why?
|
| Panax | 2 | 2017 | 33 | 0.170 |
Why?
|
| Nitriles | 1 | 2023 | 906 | 0.170 |
Why?
|
| Meditation | 1 | 2020 | 73 | 0.170 |
Why?
|
| Behavior | 1 | 2019 | 103 | 0.170 |
Why?
|
| Young Adult | 8 | 2020 | 21445 | 0.160 |
Why?
|
| Double-Blind Method | 6 | 2021 | 2588 | 0.160 |
Why?
|
| Editorial Policies | 1 | 2019 | 87 | 0.160 |
Why?
|
| Inpatients | 2 | 2022 | 678 | 0.160 |
Why?
|
| Humerus | 1 | 2018 | 53 | 0.160 |
Why?
|
| Patient Care | 1 | 2019 | 149 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2019 | 179 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 218 | 0.150 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 337 | 0.150 |
Why?
|
| Oxycodone | 1 | 2017 | 29 | 0.150 |
Why?
|
| Mortality | 1 | 2020 | 343 | 0.150 |
Why?
|
| Lorazepam | 1 | 2017 | 40 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2020 | 436 | 0.150 |
Why?
|
| Pain Measurement | 2 | 2018 | 953 | 0.150 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 15694 | 0.150 |
Why?
|
| Anti-Anxiety Agents | 1 | 2017 | 90 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 277 | 0.150 |
Why?
|
| Disease Management | 2 | 2020 | 1052 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2019 | 32848 | 0.140 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 29902 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 2019 | 256 | 0.140 |
Why?
|
| Medical Waste Disposal | 1 | 2016 | 9 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 249 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.140 |
Why?
|
| Dyspnea | 1 | 2019 | 416 | 0.140 |
Why?
|
| Hematologic Neoplasms | 3 | 2020 | 1870 | 0.140 |
Why?
|
| Administration, Oral | 2 | 2017 | 1544 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 4314 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2020 | 451 | 0.130 |
Why?
|
| Informed Consent | 1 | 2019 | 419 | 0.130 |
Why?
|
| Culture | 1 | 2016 | 100 | 0.130 |
Why?
|
| Comprehensive Health Care | 1 | 2016 | 49 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6207 | 0.130 |
Why?
|
| Checklist | 1 | 2016 | 122 | 0.130 |
Why?
|
| Terminally Ill | 1 | 2015 | 91 | 0.130 |
Why?
|
| Education, Medical | 1 | 2019 | 331 | 0.130 |
Why?
|
| Ibuprofen | 1 | 2014 | 56 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 338 | 0.120 |
Why?
|
| Medical Records | 1 | 2016 | 415 | 0.120 |
Why?
|
| Specialization | 1 | 2015 | 130 | 0.120 |
Why?
|
| Documentation | 1 | 2016 | 207 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1375 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1085 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2021 | 1411 | 0.110 |
Why?
|
| Muscle Neoplasms | 1 | 2014 | 109 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 215 | 0.110 |
Why?
|
| Anecdotes as Topic | 1 | 2012 | 11 | 0.110 |
Why?
|
| Empathy | 1 | 2014 | 101 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2017 | 661 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2018 | 631 | 0.110 |
Why?
|
| United States | 3 | 2021 | 15433 | 0.110 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 113 | 0.110 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 87 | 0.110 |
Why?
|
| Advance Directives | 1 | 2013 | 88 | 0.110 |
Why?
|
| Mental Competency | 1 | 2012 | 62 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 3472 | 0.110 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 792 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 14889 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2015 | 348 | 0.100 |
Why?
|
| Injections, Spinal | 1 | 2012 | 257 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2012 | 122 | 0.100 |
Why?
|
| Conflict of Interest | 1 | 2012 | 98 | 0.100 |
Why?
|
| Intestinal Obstruction | 1 | 2014 | 202 | 0.100 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 403 | 0.100 |
Why?
|
| Professional-Family Relations | 1 | 2012 | 134 | 0.100 |
Why?
|
| Intestinal Neoplasms | 1 | 2013 | 189 | 0.100 |
Why?
|
| Psychometrics | 1 | 2015 | 937 | 0.100 |
Why?
|
| Critical Care | 1 | 2017 | 770 | 0.100 |
Why?
|
| Osteosarcoma | 1 | 2018 | 929 | 0.090 |
Why?
|
| Goals | 2 | 2022 | 185 | 0.090 |
Why?
|
| Prescriptions | 2 | 2020 | 65 | 0.090 |
Why?
|
| Publishing | 1 | 2012 | 220 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 671 | 0.090 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2020 | 30 | 0.090 |
Why?
|
| Hospitalization | 4 | 2019 | 2083 | 0.080 |
Why?
|
| Disease Progression | 1 | 2020 | 6682 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 1 | 2012 | 423 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2013 | 1450 | 0.080 |
Why?
|
| Quality of Life | 5 | 2023 | 4532 | 0.070 |
Why?
|
| Perception | 2 | 2021 | 350 | 0.070 |
Why?
|
| Logistic Models | 1 | 2013 | 3441 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2011 | 1171 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 4320 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1664 | 0.060 |
Why?
|
| Naloxone | 1 | 2023 | 82 | 0.060 |
Why?
|
| Parents | 2 | 2020 | 998 | 0.060 |
Why?
|
| Computers | 1 | 2023 | 141 | 0.060 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 9 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2023 | 89 | 0.050 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2023 | 83 | 0.050 |
Why?
|
| Texas | 4 | 2015 | 6311 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2023 | 129 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 12926 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2023 | 553 | 0.050 |
Why?
|
| Adolescent | 3 | 2019 | 31252 | 0.050 |
Why?
|
| Urine | 1 | 2020 | 143 | 0.050 |
Why?
|
| Psychosocial Support Systems | 1 | 2020 | 7 | 0.050 |
Why?
|
| Acupuncture Points | 1 | 2020 | 18 | 0.050 |
Why?
|
| Oral Sprays | 1 | 2019 | 8 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2019 | 25 | 0.040 |
Why?
|
| Death | 1 | 2020 | 119 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 43 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 750 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 191 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 113 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 209 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 80 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 85 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 413 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 3976 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 233 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 4638 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 499 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 717 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 672 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2023 | 1145 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 15862 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 799 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2023 | 1450 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 2316 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 625 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1274 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 876 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.040 |
Why?
|
| Medical Audit | 1 | 2017 | 188 | 0.030 |
Why?
|
| Marital Status | 1 | 2015 | 98 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 1900 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 1209 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 573 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2292 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 214 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 208 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 929 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2803 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 551 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 1183 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 9180 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 2315 | 0.030 |
Why?
|
| Politics | 1 | 2012 | 74 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 5673 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 866 | 0.020 |
Why?
|
| Animals | 1 | 2014 | 59536 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 21713 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1148 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2352 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 4971 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 1544 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 4844 | 0.020 |
Why?
|
| Child | 1 | 2019 | 29154 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 14289 | 0.010 |
Why?
|